fluticasone propionate + ketotifen + montelukast sodium

This is a three-drug combination therapy used primarily for treating cough variant asthma (CVA) in children. The combination includes fluticasone propionate (a glucocorticoid steroid), ketotifen (an antihistamine), and montelukast sodium (a leukotriene receptor antagonist). Clinical studies have shown that this triple combination provides better clinical outcomes than dual combinations or single drugs, particularly at the 2-month treatment mark. The combination works by targeting multiple inflammatory pathways: fluticasone propionate reduces inflammation, ketotifen blocks histamine receptors, and montelukast sodium blocks leukotriene receptors, collectively addressing the various aspects of the allergic and inflammatory response in asthma.